Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
Acelyrin Inc (NASDAQ: SLRN) closed the day trading at $2.51 down -4.92% from the previous closing price of $2.64. In other words, the price has decreased by -$4.92 from its previous closing price. On the day, 0.52 million shares were traded. SLRN stock price reached its highest trading level at $2.65 during the session, while it also had its lowest trading level at $2.51.
Ratios:
For a better understanding of SLRN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 18.10 and its Current Ratio is at 18.10. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, H.C. Wainwright on August 14, 2024, Downgraded its rating to Neutral and sets its target price to $6 from $18 previously.
On July 08, 2024, Wells Fargo Upgraded its rating to Overweight which previously was Equal Weight but kept the price unchanged to $13.
On December 13, 2023, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $11.Wells Fargo initiated its Equal Weight rating on December 13, 2023, with a $11 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 17 ’25 when Kim Mina sold 17,986 shares for $2.74 per share. The transaction valued at 49,354 led to the insider holds 671,753 shares of the business.
Murugan Amar sold 3,913 shares of SLRN for $10,737 on Mar 17 ’25. The Chief Legal Officer now owns 121,587 shares after completing the transaction at $2.74 per share. On Mar 17 ’25, another insider, Mpofu Shephard, who serves as the Chief Medical Officer of the company, sold 3,211 shares for $2.74 each. As a result, the insider received 8,811 and left with 121,789 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLRN now has a Market Capitalization of 265874256 and an Enterprise Value of -187794272.
Stock Price History:
The Beta on a monthly basis for SLRN is 1.13, which has changed by -0.62814814 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, SLRN has reached a high of $7.30, while it has fallen to a 52-week low of $1.85. The 50-Day Moving Average of the stock is 8.76%, while the 200-Day Moving Average is calculated to be -40.29%.
Shares Statistics:
Over the past 3-months, SLRN traded about 2.23M shares per day on average, while over the past 10 days, SLRN traded about 854540 shares per day. A total of 100.45M shares are outstanding, with a floating share count of 73.01M. Insiders hold about 27.51% of the company’s shares, while institutions hold 76.07% stake in the company. Shares short for SLRN as of 1740700800 were 4301951 with a Short Ratio of 1.93, compared to 1738281600 on 5868409. Therefore, it implies a Short% of Shares Outstanding of 4301951 and a Short% of Float of 4.8899997.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The company has 1.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.71, with high estimates of -$0.71 and low estimates of -$0.71.
Analysts are recommending an EPS of between -$2.4 and -$2.4 for the fiscal current year, implying an average EPS of -$2.4. EPS for the following year is -$2.01, with 1.0 analysts recommending between -$2.01 and -$2.01.
